Search

Displaying results 3521 - 3530 of 9886 in total
  1. Drug

    SYNB1891

    go.drugbank.com/drugs/DB17541
    Investigational

    SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway.

  2. Drug

    Mequitazine

    go.drugbank.com/drugs/DB01071
    Investigational

    Mequitazine is a histamine H1 antagonist (antihistamine). … It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

  3. Drug

    Reproxalap

    go.drugbank.com/drugs/DB16688
    Investigational

    [L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990] … Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis

  4. Drug

    Brincidofovir

    go.drugbank.com/drugs/DB12151
    ApprovedInvestigational

    [A235725,A235735] Due to its formulation as a pro-drug brincidofovir also carries a greater bioavailability than cidofovir,[A235740,A235725] allowing for oral administration rather than intravenous. … It is a lipid conjugate pro-drug of the acyclic nucleotide analogue [cidofovir][L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity

  5. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. … Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK).

  6. Drug

    AZD-6482

    go.drugbank.com/drugs/DB14980
    Investigational

    AZD-6482 is under investigation in clinical trial NCT00688714 (Study to Investigate Safety and Tolerability of a Single Dose of AZD6482).

    Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors
  7. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current therapies do not cross the blood-brain barrier … RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.

  8. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016].

  9. Drug

    Enrofloxacin

    go.drugbank.com/drugs/DB11404
    InvestigationalVet approved

    Due to the identification of fluoroquinolone-resistant strains of _Campylobacter_, in September 2005, the FDA withdrew the approval of enrofloxacin for its use in water to treat flocks of poultry.

  10. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline.